Medtronic Says No Increased Risk of Blood Clots On Early Cessation of Dual Antiplatelet Therapy

by Benzinga Staff
October 22, 2012 10:03 AM | 15 seconds read | Make a Comment

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

Interrupting dual antiplatelettherapy after 30 days following the implantation of a Resolute drug-elutingstent from Medtronic, Inc. (NYSE: MDT) caused no increase in rates of stentthrombosis at one year, according to a new analysis of the global RESOLUTEclinical program presented today at the 24th Annual TranscatheterCardiovascular Therapeutics (TCT) scientific symposium.

27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: NewsFDA

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.